A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT- dgA) in patients with refractory Hodgkin's lymphoma

Blood

Volumn 89, Issue 2, 1997, Pages 403-410

  Engert, Andreas ^a   Diehl, Volker ^b   Schnell, Roland ^b   Radszuhn, Andrea ^b   Hatwig, Maria Theresia ^b   Drillich, Silke ^b   Schön, Gisela ^b   Bohlen, Heribert ^b   Tesch, Hans ^b   Hansmann, Martin Leo ^b   Barth, Stefan ^b   Schindler, John ^b   Ghetie, Victor ^b   Uhr, Jonathan ^b   Vitetta, Ellen ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; RICIN A;

ADULT; ARTICLE; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; EDEMA; EXTRAVASATION; FEMALE; HODGKIN DISEASE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUSCLE WEAKNESS; MYALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TACHYCARDIA; URTICARIA;

EID: 0031037004     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.2.403     Document Type: Article

References (44)

1. DeVita VT, Serpick A, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:891, 1970
2. Bonadonna G, Santoro A: ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 9:21, 1982
3. Kaplan HS: Hodgkin's disease: Unfolding concepts concerning its nature, management and prognosis. Cancer 45:2439, 1980
4. Carella AM: Indications for autologous BMT in Hodgkin's disease. Leuk Lymphoma 7:21, 1992
5. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051, 1993
6. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte R, the German Cancer Aid 17-1A Study Group: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177, 1994
7. Roy DC, Griffin JD, Belvin M, Blättler WA, Lambert JM, Ritz J: Anti-My9-blocked ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 77:2404, 1991
8. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525, 1991
9. Stein H, Schwarting R, Dallenbach F, Dienemann D: Immunology of Hodgkin and Reed-Sternberg cells. Recent Results Cancer Res 117:14, 1989
10. Hsu SM, Ho YS, Hsu PL: Effect of monoclonal antibodies anti-2H9, anti-IRac, and anti-HeFi-1 on the surface antigens of Reed-Sternberg cells. J Natl Cancer Inst 79:1091, 1987
11. Vitetta ES, Fulton RJ, May RD, Till M, Uhr JW: Redesigning nature's poisons to create anti-tumor reagents. Science 238:1098, 1987
12. Taniguchi T, Minami Y: The IL-2/IL-2 receptor system: A current overview. Cell 73:5, 1993
13. Cosman D, Lyman SD, Idzerda RJ, Beckmann MP, Park LS, Goodwin RG, March CJ: A new cytokine receptor superfamily. Trends Biochem Sci 15:265, 1990
14. Diamantstein T, Osawa H: The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppessive therapy by anti-interleukin-2 receptor monoclonal antibodies. Immunol Rev 92:5, 1986
15. Strauchen JA, Breakstone BA: IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol 126:506, 1987
16. Barth S, Schnell R, Diehl V, Engert A: Development of immunotoxins for potential clinical use in Hodgkin's disease. Ann Oncol 7:135, 1996 (suppl 4)
17. Engert A, Martin G, Amlot P, Wijdenes J, Diehl V, Thorpe P: Immunotoxins constructed with CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent antitumor effects against human Hodgkin cells in vitro and solid Hodgkin tumors in mice. Int J Cancer 49:450, 1991
18. Winkler U, Gottstein C, Schön G, Kapp U, Wolf J, Hansmann ML, Bohlen H, Thorpe P, Diehl V, Engert A: Successful treatment of disseminated human Hodgkin's disease in SCID mice using deglycosylated ricin A-chain immunotoxins. Blood 83:466, 1994
19. Engert A, Gottstein C, Winkler U, Amlot P, Pileri S, Diehl V, Thorpe P: Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins. Leuk Lymphoma 13:441, 1994
20. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V, Schindler J, Uhr JW, Wittes RE, Vitetta ES: Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase-I study. Blood 85:3457, 1995
21. Schumaker RC: A basic interactive complex program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 17:331, 1986
22. Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D, Ghetie V, Uhr J, Thorpe P: Phase-I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51:4052, 1991
23. Amlot P, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, Ramillo O, Thorpe P, Uhr J, Vitetta ES: A phase-I study of an anti-CD22-deglycosylated ricin A-chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82:2624, 1993
24. Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM, Senderowilz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES: A phase -I study of bolus vs. continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA in patients with B cell lymphoma. Blood 88:1188, 1996
25. Vitetta ES, Thorpe PE, Uhr JW: Immunotoxins: Magic bullets or misguided missiles? Immunol Today 14:252, 1993
26. Durrant LG, Byers VS, Scannon PJ, Rodvien R, Grant K, Robins RA, Marksman RA, Baldwin RW: Humoral immune responses to XMMCO-791-RTA immunotoxins in colorectal cancer patients. Clin Exp Immunol 75:258, 1989
27. Byers VS, Bardwin RW: Rationale for clinical use of immunotoxins in cancer and autoimmune diseases. Semin Cell Biol 2:59, 1991
28. Junghans RP, Waldmann TA: Metabolism of TAc (IL2Rα): Physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med 185:1587, 1996
29. Kreitmann RJ, Chaudhary VK, Kozak RW, FitzGerald DJP, Waldmann TA, Pastan I: Recombinant toxins containing the variable domains of the anti-tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood 80:2344, 1992
30. Kreitmann RJ, Chaudhary VK, Waldmann TA, Hanchard B, Cranston B, FitzGerald DJP, Pastan I: Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or Diphteria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia 7:553, 1993
31. 486IL-2 in advanced mycosis fungoides and the sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase-II study. Blood 84:1765, 1994
32. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR: Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Prot Eng 1:493, 1987
33. LeMaistre F, Craig FE, Meneghetti CM, McMullin B, Parker K, Reuben J, Boldt DH, Rosenblum M, Woodworth T: Phase-I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res 53:3930, 1993
34. 486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 73:1276, 1994
35. Foss F, Nichols J, Parker K, the Seragen Lymphoma Study Group: Phase-I/II trial of DAB389IL-2 in patients with NHL, HD and CTCL. Fourth International Symposium on Immunotoxins, 1995, p 159A
36. Falini B: Anti-CD30 immunotoxins: Experimental and clinical studies. Fourth International Symposium on Immunotoxins, 1995, p 160A
37. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Dürkopp H: Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339:1195, 1992
38. Engert A, Burrows F, Jung W, Tazzari PL, Stein H, Pfreundschuh M, Diehl V, Thorpe P: Evaluation of ricin A-chain containing immunotoxins directed against CD30 as potential reagents for the treatment of Hodgkin's disease. Cancer Res 50:84, 1990
39. Engert A, Martin G, Pfreundschuh M, Amlot P, Hsu SM, Diehl V, Thorpe P: Antitumor effects of ricin A-chain immunotoxins from intact antibodies and Fab′ fragments on solid human Hodgkin's disease tumors in mice. Cancer Res 50:2929, 1990
40. Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, Sterry W, Parwaresch RM, Lemke H: Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 60:539, 1995
41. Schnell R, Linnartz C, Schön G, Katouzi A, Bohlen H, Horn-Lohrens O, Parwaresch R, Diehl V, Lemke H, Engert A: Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer 63:238, 1995
42. Engert A, Gottstein C, Bohlen H, Winkler U, Schön G, Manske O, Schnell R, Diehl V, Thorpe P: Cocktails composed of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed (H-RS) cells have superior antitumor effects against H-RS cells in vitro and solid Hodgkin's tumors in mice. Int J Cancer 63:304, 1995
43. Katz FE, Janossy G, Cumber A, Ross W, Blacklock HA, Tax W, Thorpe PE: Elimination of T cells from human peripheral blood and bone marrow using a cocktail of three anti-T cell immunotoxins. Br J Haematol 67:407, 1987
44. Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES: The antitumor activity of an anti-CD 22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 80:2315, 1992